Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

KVK Tech is an FDA-approved pharmaceutical manufacturer specializing in formulation development, CMC execution, and large-scale commercial production. As Sen-Jam's corporate venture partner, KVK Tech ...

Mark Manfredi brings over two decades of international biopharmaceutical industry leadership and cancer drug discovery success to DISCOFinancing ...

Learn more about whether Amneal Pharmaceuticals, Inc. or Wave Life Sciences Ltd. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.

Ironwood Pharma remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess giving strong recurring revenue. Learn more about IRWD stock here.

The average one-year price target for Takeda Pharmaceutical Company (OTCPK:TKPHF) has been revised to $31.95 / share. This is a decrease of 10.12% from the prior estimate of $35.55 dated September 12, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. In this episode of PNC C-Speak, Christophe Weber, president ...

A global pharmaceutical distribution company is expanding its Dothan operations as part of a companywide $1 billion expansion throughout the U.S. Pennsylvania-based Cencora Wednesday announced it will ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. Roche licensed a respiratory bispecific candidate in ...

Chinese drugmaker Innovent Biologics could receive up to US$11.4 billion from a cancer-drug partnership with Japan's Takeda Pharmaceutical, marking the latest in a wave of tie-ups between Chinese ...

Takeda is paying Innovent Biologics $1.2 billion upfront for rights to two cancer candidates. The deal, which includes (PDF) $10.2 billion in milestones, puts the biologics at the center of Takeda’s ...